Sirnaomics Reports the Completion Patient Dosing of STP707 in P-I Study for Treatment of Multiple Solid Tumors
Shots:
- This dose-escalation evaluated the safety, tolerability, and antitumor activity of STP707 in enrolled patients (n=50) with late-stage solid tumors who did not respond to prior line of therapies in the US at different doses (3 mg, 6 mg, 12 mg, 24 mg, 36 mg and 48 mg IV, QW for a total of four doses over a 28-day treatment cycle)
- Preliminary efficacy results demonstrated the best response of SD (74%) of evaluable patients and several patients exhibited reduction in tumor burden per RECIST and No DLTs were observed after completing the observation period
- STP707 comprises two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively, formulated in nanoparticles with a Histidine-Lysine Co-Polymer peptide as the carrier
Ref: Sirnaomics | Image: Sirnaomics
Related News:- Innovent Signs a Clinical Trial Agreement with Sirnaomics to Treat Cancer and Fibrotic Diseases in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
